{'52WeekChange': 0.48609376,
 'SandP52WeekChange': 0.0644362,
 'address1': '170 Harbor Way',
 'address2': '3rd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 35.99,
 'askSize': 800,
 'averageDailyVolume10Day': 274512,
 'averageVolume': 353092,
 'averageVolume10days': 274512,
 'beta': None,
 'beta3Year': None,
 'bid': 33.18,
 'bidSize': 1100,
 'bookValue': 4.127,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 36.51,
 'dayLow': 34.98,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 901461440,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 30.629715,
 'fiftyTwoWeekHigh': 41.16,
 'fiftyTwoWeekLow': 10.78,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14172809,
 'forwardEps': -3.68,
 'forwardPE': -9.72826,
 'fromCurrency': None,
 'fullTimeEmployees': 13,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.09508,
 'heldPercentInstitutions': 0.84226996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/akerotx.com',
 'longBusinessSummary': 'Akero Therapeutics, Inc., a clinical-stage '
                        'biotechnology company, engages in the development and '
                        'commercialization of treatments for serious metabolic '
                        'diseases. Its lead product candidate is AKR-001, '
                        'which is in Phase IIa clinical trial for the '
                        'treatment of nonalcoholic steatohepatitis disease.The '
                        'company was formerly known as Pippin Pharmaceuticals, '
                        'Inc. and changed its name to Akero Therapeutics, Inc. '
                        'in May 2018. Akero Therapeutics, Inc. was founded in '
                        '2017 and is headquartered in South San Francisco, '
                        'California.',
 'longName': 'Akero Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1242120320,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_571820600',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -50279000,
 'nextFiscalYearEnd': 1640908800,
 'open': 35.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 487 6488',
 'previousClose': 35.82,
 'priceHint': 2,
 'priceToBook': 8.6745825,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 36.51,
 'regularMarketDayLow': 34.98,
 'regularMarketOpen': 35.41,
 'regularMarketPreviousClose': 35.82,
 'regularMarketPrice': 35.41,
 'regularMarketVolume': 177114,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 34696100,
 'sharesPercentSharesOut': 0.039,
 'sharesShort': 1119768,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 569275,
 'shortName': 'Akero Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0861,
 'shortRatio': 4.44,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'AKRO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.27,
 'twoHundredDayAverage': 23.972841,
 'volume': 177114,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.akerotx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}